Does Blue Cross Blue Shield of Michigan Cover Liraglutide (Saxenda)?

What Is Liraglutide (Saxenda) and Why Does Coverage Matter?

Liraglutide 3 mg (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA on December 23, 2014, specifically for chronic weight management. The drug is distinct from the 1.8 mg formulation used for type 2 diabetes (Victoza). In the SCALE Obesity and Prediabetes trial (N=3,731), patients receiving liraglutide 3 mg lost a mean of 8.0% of body weight at 56 weeks compared with 2.6% in the placebo group (P<0.001) [1]. Roughly 63% of liraglutide-treated patients achieved at least 5% weight loss versus 27% on placebo [1].

Coverage matters because the retail price of one 30-day supply of Saxenda sits between $1,350 and $1,450 as of mid-2025. Patients typically need 12 to 24 months of continuous therapy to realize and maintain clinically meaningful weight loss [2]. Without insurance, that translates to $16,000 to $34 to 000 in medication costs alone before any dose adjustments or prescriber fees.

Blue Cross Blue Shield of Michigan (BCBSM) is the dominant commercial insurer in Michigan, covering approximately 4.5 million lives across fully insured and self-funded employer plans. Whether Saxenda appears on your specific formulary depends on the plan type, employer decisions, and whether you are on a commercial, Medicare Advantage, or Medicaid product. The sections below walk through each variable in order.

FDA-Approved Indications: The Clinical Baseline for Coverage

BCBSM's medical and pharmacy policies are anchored to FDA-labeled indications. The FDA approved liraglutide 3 mg as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater, or BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia [3].

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity, updated in 2022, recommends GLP-1 receptor agonists as first- or second-line adjuncts when lifestyle modification alone produces insufficient weight loss [4]. BCBSM's own pharmacy benefit managers frequently reference these guidelines when building prior-authorization criteria. Aligning your clinical documentation with the FDA label and Endocrine Society thresholds is the most reliable way to satisfy an insurer's medical necessity requirements.

Saxenda is not approved for patients under 18 years who weigh <60 kg, though a pediatric indication for adolescents 12 and older was added in December 2020 [3]. If you are filing on behalf of an adolescent patient, BCBSM may apply a separate pediatric prior-authorization policy.

How BCBSM Formularies Work for Weight-Loss Drugs

BCBSM administers pharmacy benefits through its subsidiary Blue Care Network and through national pharmacy benefit managers. Commercial plans use a tiered formulary. Saxenda, when covered, generally lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays for a 30-day supply on BCBSM commercial plans typically range from $60 to $100 after deductible; Tier 4 copays range from $100 to $200 [5].

Self-funded employer plans are a critical exception. Under the Employee Retirement Income Security Act (ERISA), self-insured employers design their own benefit structures, and BCBSM administers the plan without bearing financial risk. Many Michigan employers exclude anti-obesity medications entirely from their formularies. The 2023 IQVIA Institute report found that only 28% of employer-sponsored plans covered any GLP-1 weight-loss agent [6]. If your plan is self-funded and excludes Saxenda, BCBSM cannot override that exclusion through an appeal, though your employer's HR department can petition for a formulary amendment.

To check your specific formulary, log into your BCBSM member portal and search the drug formulary tool by NDC code 00169-2850-02 (the 5-pen Saxenda carton). The formulary tier, any quantity limits, and the prior-authorization flag will appear in the search results.

Prior Authorization Criteria BCBS Michigan Typically Requires

Prior authorization (PA) is required on virtually every BCBSM plan that covers Saxenda. Based on published BCBSM pharmacy medical policies and standard industry PA criteria, expect the following documentation requirements [5].

Diagnosis and BMI documentation. The prescribing clinician must submit a chart note confirming BMI ≥30 kg/m², or BMI ≥27 kg/m² with a documented comorbidity. A recent (within 90 days) weight and height measurement in the medical record is typically required. A telehealth visit with a calibrated scale reading submitted as part of the note may satisfy this requirement on some plans.

Failure of lifestyle intervention. BCBSM typically requires documentation of at least three to six months of structured dietary counseling or a supervised weight-management program before approving a GLP-1 weight-loss agent. Records from a registered dietitian, a YMCA Diabetes Prevention Program, or a physician-supervised low-calorie diet program fulfill this criterion. The Centers for Disease Control and Prevention (CDC) National Diabetes Prevention Program is one accepted format [7].

Prescriber specialty. Some BCBSM PA forms require that the prescribing physician be a primary care provider, endocrinologist, or obesity medicine specialist. Prescriptions from other specialty types may trigger additional review.

Absence of contraindications. The prescriber must attest that the patient has no personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, both listed in Saxenda's FDA boxed warning [3].

Concurrent diabetes medications. Because liraglutide is also marketed as Victoza for type 2 diabetes, BCBSM will not approve Saxenda simultaneously with Victoza. If a patient is on liraglutide 1.8 mg for diabetes, the PA request must clarify that the 3 mg weight-management indication is the intended use and that only one formulation will be dispensed.

The HealthRX clinical team assembled the following checklist based on PA denial patterns observed across Michigan GLP-1 prescriptions. Gather these items before submitting to reduce denial rates.

1. Dated chart note with current weight (kg), height (cm), and calculated BMI.
2. ICD-10 code E66.01 (morbid obesity) or E66.09 (other obesity) plus any comorbidity code (e.g., I10 for hypertension).
3. Lifestyle intervention records spanning at least 90 days (preferably 180 days).
4. Letter of medical necessity signed by the treating physician, referencing the SCALE trial data and the Endocrine Society guideline recommendation.
5. Completed BCBSM PA form (available through the provider portal at provider.bcbsm.com).
6. If applicable, documentation that the patient cannot tolerate or has not responded to other covered weight-loss agents (phentermine-topiramate, naltrexone-bupropion).

Submitting all six items in the initial PA request, rather than waiting for a deficiency notice, shortens the average review cycle from 10 to 14 business days down to 3 to 5 business days in most cases.

What BCBSM's Coverage Policy Actually Says About Anti-Obesity Medications

BCBSM publishes medical and pharmacy coverage policies on its provider portal. The anti-obesity medication policy, policy number MP-6.01.73, was most recently updated in early 2024. The policy states that pharmacological treatment of obesity is covered as a pharmacy benefit when prior-authorization criteria are met, and specifies that FDA-approved chronic weight-management agents, including liraglutide 3 mg, are eligible for coverage on plans that include the weight-management pharmacy benefit [5].

The American Academy of Family Physicians (AAFP) position statement on obesity management, adopted in 2020, calls obesity a chronic disease requiring the same long-term medical management as hypertension or hyperlipidemia [8]. Citing this position statement in a letter of medical necessity reinforces the argument that denying coverage for an FDA-approved treatment is inconsistent with evidence-based chronic disease management standards.

"Obesity is a chronic, relapsing, and treatable disease. The primary goal of treatment is to improve health, not simply to reduce body weight," states the Obesity Medicine Association's 2023 position statement on obesity pharmacotherapy [9]. Quoting this language in an appeal letter contextualizes the request as medically necessary disease management rather than cosmetic intervention.

Medicare Advantage and Medicaid Coverage in Michigan

Standard Medicare Part D has historically excluded weight-loss medications, including Saxenda, under the Medicare Modernization Act's exclusion of drugs "used for anorexia, weight loss, or weight gain" [10]. The Treat and Reduce Obesity Act (TROA), if passed, would reverse this exclusion, but as of mid-2025 it has not been enacted into law.

Some BCBS Michigan Medicare Advantage plans include supplemental pharmacy benefits that cover anti-obesity medications as an enhanced benefit. Check your Evidence of Coverage document under "Part D Formulary" or call the number on the back of your Medicare Advantage card to ask specifically whether liraglutide 3 mg (NDC 00169-2850-02) is covered. If your Medicare Advantage plan does cover Saxenda, PA criteria still apply and are generally similar to commercial plan requirements.

Michigan Medicaid (Healthy Michigan Plan) administered through Blue Care Network covers FDA-approved anti-obesity medications for adults meeting BMI criteria, following the Michigan Department of Health and Human Services (MDHHS) pharmacy benefit criteria. The Medicaid PA form requires additional documentation of a comorbid condition and typically sets a six-month lifestyle intervention requirement before approving a GLP-1 agent [7].

How to Handle a Coverage Denial

Denial rates for weight-loss medication PAs remain high nationally. A 2022 analysis published in JAMA Health Forum found that anti-obesity medication PA requests were denied at rates exceeding 25% on first submission, with the most common reason being insufficient documentation of prior lifestyle intervention [11].

BCBSM is required under Michigan insurance law and the Affordable Care Act to provide a written denial notice within specific timeframes: 72 hours for urgent requests and 15 calendar days for standard PA requests. The denial notice must include the specific clinical rationale and the criteria the request failed to meet.

Level 1 internal appeal. File a written appeal within 180 days of the denial date. Include all six items from the checklist above plus any new clinical information, peer-reviewed literature (the SCALE trial [1] and the Endocrine Society guideline [4] are strong anchors), and a detailed letter of medical necessity. BCBSM must issue a Level 1 decision within 30 days for standard appeals.

Level 2 external independent review. If the Level 1 appeal is denied, you may request an independent external review through the Michigan Department of Insurance and Financial Services (DIFS). External reviewers overturn internal denials at meaningful rates. The American Heart Association's 2022 report on insurance barriers to obesity care found that approximately 40% of externally reviewed anti-obesity medication denials were overturned in the patient's favor [12].

Peer-to-peer review. Before filing a formal appeal, request a peer-to-peer call between your prescribing physician and the BCBSM medical director who issued the denial. These calls resolve a substantial number of denials at the lowest administrative burden. Ask the prescriber to quote the Endocrine Society 2022 guideline classification of obesity as a chronic disease requiring pharmacotherapy when lifestyle modification is insufficient [4].

Cost Strategies When Coverage Is Denied or Unavailable

Even with a denial in progress, patients can pursue cost reduction through several channels.

Novo Nordisk Saxenda Savings Card. Commercially insured patients who are not enrolled in a government program (Medicare, Medicaid, CHIP, TRICARE) may pay as little as $25 per month for Saxenda through the manufacturer savings program. The savings card is available at saxenda.com and can be processed at any participating retail pharmacy.

Patient Assistance Program. Uninsured or underinsured patients with household income below 400% of the federal poverty level may qualify for Novo Nordisk's NovoCare Patient Assistance Program, which provides Saxenda at no cost. Applications are processed through novocare.com.

GoodRx and pharmacy discount cards. GoodRx prices for Saxenda (5-pen carton) vary by pharmacy and zip code but typically range from $950 to $1,100, representing a 25 to 30% discount from retail price. This does not apply if you are using insurance.

Compounded liraglutide. The FDA issued guidance in 2023 and 2024 regarding compounded GLP-1 medications. Compounded liraglutide is not FDA-approved for safety and efficacy, and the FDA has flagged safety concerns with compounded GLP-1 products [13]. HealthRX does not recommend compounded liraglutide as a substitute for FDA-approved Saxenda.

Step therapy alternatives. If your plan requires step therapy, orlistat 120 mg (Xenical) is often the first required step. Naltrexone-bupropion ER (Contrave) and phentermine-topiramate ER (Qsymia) are common second steps. Documenting a trial and inadequate response to these agents, or documenting a contraindication, satisfies most step-therapy requirements and opens the path to Saxenda approval.

Clinical Outcomes Data That Supports the Coverage Case

Payers respond to outcomes data. Three trials are particularly useful in prior-authorization letters and appeals.

The SCALE Obesity and Prediabetes trial (N=3,731) showed that liraglutide 3 mg produced a mean weight loss of 8.0% at 56 weeks versus 2.6% with placebo (P<0.001) [1]. Patients losing 5% or more of baseline weight showed significant improvements in waist circumference, blood pressure, fasting glucose, and lipids, all of which reduce downstream claims costs for cardiovascular events and type 2 diabetes.

The SCALE Diabetes trial (N=846) enrolled patients with type 2 diabetes and BMI ≥27 kg/m² [14]. Liraglutide 3 mg produced 6.0% weight loss versus 2.0% with placebo at 56 weeks. Hemoglobin A1c fell by 1.3 percentage points in the liraglutide group, a clinically meaningful reduction that reduces the probability of costly microvascular complications [14].

The SCALE Maintenance trial (N=422) showed that patients who lost at least 5% of body weight during a 12-week low-calorie diet run-in phase regained significantly less weight when continuing liraglutide 3 mg than when switched to placebo over 56 weeks (2.8% regain vs. 7.2% regain, P<0.001) [15]. This trial directly addresses the insurer concern that weight-loss medications provide only transient benefit, demonstrating durable maintenance with continued treatment [15].

Presenting all three trials in a letter of medical necessity, with a brief note that each 1% reduction in body weight is associated with a $200 to $300 reduction in annual diabetes-related medical costs per the CDC's economic analyses [7], strengthens the actuarial argument that covering Saxenda reduces total cost of care.

Switching From Saxenda to Wegovy: A Coverage Consideration

Semaglutide 2.4 mg (Wegovy), also a GLP-1 receptor agonist, was approved by the FDA in June 2021 for chronic weight management. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [16]. The effect size is roughly double that of liraglutide 3 mg, and the once-weekly injection schedule has better adherence profiles than once-daily liraglutide in most comparative analyses.

BCBSM formularies are evolving. Some plans now prefer Wegovy over Saxenda as the covered GLP-1 weight-loss agent, placing Saxenda on a non-preferred tier or removing it entirely while adding Wegovy to Tier 3. If your BCBSM plan denies Saxenda but your prescriber is open to semaglutide, checking Wegovy's formulary status before filing a Saxenda appeal may save weeks of administrative time. The PA criteria for Wegovy are broadly similar to Saxenda, anchored to the same BMI and comorbidity thresholds [3].

Practical Timeline for Getting Saxenda Approved Through BCBSM

A realistic timeline from first prescriber visit to first dispensed prescription, assuming no complications, runs approximately 30 to 45 days.

Days 1 to 7: Initial prescriber visit with weight measurement, BMI calculation, comorbidity documentation, and lifestyle intervention records gathered.

Days 8 to 14: Prescriber or office staff submits completed PA form through the BCBSM provider portal. A letter of medical necessity accompanies the submission.

Days 15 to 19: BCBSM standard PA review period (up to 15 calendar days allowed under Michigan law; median actual review time is closer to 5 to 7 business days for complete submissions).

Days 20 to 25: If approved, prescription transmitted electronically to a participating pharmacy. Specialty pharmacies contracted with BCBSM include CVS Caremark and Walgreens specialty channels for temperature-controlled injectable delivery.

Days 26 to 45: If denied, peer-to-peer call requested within 3 business days of denial. Level 1 appeal filed concurrently with additional documentation. Level 1 review period up to 30 days.

Patients should not delay starting lifestyle modifications while waiting for PA approval. Enrolling in a CDC-recognized Diabetes Prevention Program during the PA period generates concurrent documentation of structured lifestyle intervention, satisfying one of the most commonly deficient PA criteria.